Medical marijuana may lead to health-related quality of life improvements, according to a new study, published in the journal Behavioral Medicine, which is titled Perceived efficacy of medical cannabis in the treatment of co-occurring health-related quality of life symptom.
For the study researchers (DePaul University and Johns Hopkins University) studied 367 patients who were all enrolled in Illinois’ medical marijuana program. According to researchers participants reported that marijuana was efficacious in relieving symptoms related to depression, anxiety, pain and insomnia. Patients suffering from multiple symptoms were most likely to find relief from marijuana use.
“In terms of therapeutic value, our findings suggest that the wider the range of symptoms [that] a patient reports, the more likely that it is that they will perceive benefit from MC (medical cannabis)”, states the study. “Our results suggest that comorbid pain, anxiety, and depression may be particularly amenable to treatment with MC.”
The full abstract of the study can be found below:
For persons living with chronic conditions, health-related quality of life (HRQoL) symptoms, such as pain, anxiety, depression, and insomnia, often interact and mutually reinforce one another. There is evidence that medical cannabis (MC) may be efficacious in ameliorating such symptoms and improving HRQoL. As many of these HRQoL symptoms may mutually reinforce one another, we conducted an exploratory study to investigate how MC users perceive the efficacy of MC in addressing co-occurring HRQoL symptoms. We conducted a cross-sectional online survey of persons with a state medical marijuana card in Illinois (N = 367) recruited from licensed MC dispensaries across the state. We conducted tests of ANOVA to measure how perceived MC efficacy for each HRQoL symptom varied by total number of treated symptoms reported by participants. Pain was the most frequently reported HRQoL treated by MC, followed by anxiety, insomnia, and depression. A large majority of our sample (75%) reported treating two or more HRQoL symptoms. In general, perceived efficacy of MC in relieving each HRQoL symptom category increased with the number of co-occurring symptoms also treated with MC. Perceived efficacy of MC in relieving pain, anxiety, and depression varied significantly by number of total symptoms experienced. This exploratory study contributes to our understanding of how persons living with chronic conditions perceive the efficacy of MC in treating co-occurring HRQoL symptoms. Our results suggest that co-occurring pain, anxiety, and depression may be particularly amenable to treatment with MC.